New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
08:08 EDTVRXValeant acquires U.S. rights to Targretin from Eisai for $65M
Eisai and Valeant announced that Valeant has acquired U.S. rights for Targretin capsules and Targretin gel 1% from Eisai for $65M upfront, plus potential contingent payments based on certain milestones. As part of the transaction, which takes effect immediately, Eisai has transferred the New Drug Application for Targretin to Valeant, with Valeant assuming responsibilities for all regulatory obligations associated with the product in the United States. Eisai will retain its rights to Targretin outside of the United States and continue to meet the needs of its distribution partners outside of the United States.
News For VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
06:19 EDTVRXPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use